Joint TOS/OMA/OAC expert guidance statement on the pharmacological management of United States adults with overweight or obesity using the GRADE approach - PubMed
7 hours ago
- #obesity
- #GRADE approach
- #pharmacological management
- Obesity affects over 40% of US adults, with severe obesity increasing.
- Obesity is underdiagnosed and undertreated despite being recognized as a chronic disease.
- Barriers to treatment include socioeconomic disparities, limited clinician training, stigma, and reimbursement issues.
- FDA-approved obesity medications provide significant health benefits but are underutilized.
- A multidisciplinary panel used the GRADE approach to develop evidence-based guidance on obesity medications.
- Strong recommendations were made for bupropion-naltrexone, semaglutide, tirzepatide, and setmelanotide.
- Conditional recommendations were given for other medications and specific obesity-related complications.
- Continuing obesity medications during weight maintenance received a strong recommendation.
- Future priorities include improving access, affordability, and integrating obesity care into primary care settings.